JPWO2019217145A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019217145A5 JPWO2019217145A5 JP2020562110A JP2020562110A JPWO2019217145A5 JP WO2019217145 A5 JPWO2019217145 A5 JP WO2019217145A5 JP 2020562110 A JP2020562110 A JP 2020562110A JP 2020562110 A JP2020562110 A JP 2020562110A JP WO2019217145 A5 JPWO2019217145 A5 JP WO2019217145A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- polypeptide sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 124
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 124
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 124
- 239000000427 antigen Substances 0.000 claims description 104
- 102000036639 antigens Human genes 0.000 claims description 104
- 108091007433 antigens Proteins 0.000 claims description 104
- 239000012634 fragment Substances 0.000 claims description 85
- 229940127276 delta-like ligand 3 Drugs 0.000 claims description 79
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 claims description 57
- 102100036466 Delta-like protein 3 Human genes 0.000 claims description 51
- 206010028980 Neoplasm Diseases 0.000 claims description 36
- 210000004027 cell Anatomy 0.000 claims description 33
- 201000011510 cancer Diseases 0.000 claims description 31
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 30
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 230000001404 mediated effect Effects 0.000 claims description 10
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims description 9
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims description 9
- 206010057249 Phagocytosis Diseases 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- 210000002540 macrophage Anatomy 0.000 claims description 8
- 230000008782 phagocytosis Effects 0.000 claims description 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 7
- 102000053255 human DLL3 Human genes 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 230000000903 blocking effect Effects 0.000 claims description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 210000003743 erythrocyte Anatomy 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 102000044459 human CD47 Human genes 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 230000007115 recruitment Effects 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 230000006037 cell lysis Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 102000034356 gene-regulatory proteins Human genes 0.000 claims 1
- 108091006104 gene-regulatory proteins Proteins 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862668427P | 2018-05-08 | 2018-05-08 | |
| US62/668,427 | 2018-05-08 | ||
| US201862754207P | 2018-11-01 | 2018-11-01 | |
| US62/754,207 | 2018-11-01 | ||
| US201962787815P | 2019-01-03 | 2019-01-03 | |
| US62/787,815 | 2019-01-03 | ||
| PCT/US2019/029888 WO2019217145A1 (en) | 2018-05-08 | 2019-04-30 | Anti-dll3 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021528047A JP2021528047A (ja) | 2021-10-21 |
| JPWO2019217145A5 true JPWO2019217145A5 (de) | 2022-05-02 |
| JP7455388B2 JP7455388B2 (ja) | 2024-03-26 |
Family
ID=68467536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020562110A Active JP7455388B2 (ja) | 2018-05-08 | 2019-04-30 | 抗ｄｌｌ３抗体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210047399A1 (de) |
| EP (1) | EP3790586A4 (de) |
| JP (1) | JP7455388B2 (de) |
| KR (1) | KR20210008367A (de) |
| CN (1) | CN112584860B (de) |
| AU (1) | AU2019267349A1 (de) |
| BR (1) | BR112020021280A2 (de) |
| CA (1) | CA3097193A1 (de) |
| MX (1) | MX2020011914A (de) |
| SG (1) | SG11202009772PA (de) |
| WO (1) | WO2019217145A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240004860A (ko) * | 2021-05-08 | 2024-01-11 | 상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 | 디엘엘3에 대한 결합 분자 및 이의 용도 |
| AU2022317608A1 (en) * | 2021-07-30 | 2024-03-14 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Anti-dll3 antibody and preparation method therefor, drug conjugate and application thereof |
| WO2023041041A1 (en) * | 2021-09-17 | 2023-03-23 | Wuxi Biologics (Shanghai) Co., Ltd. | D3-binding molecules and uses thereof |
| WO2023116861A1 (zh) * | 2021-12-23 | 2023-06-29 | 江苏恒瑞医药股份有限公司 | 抗dll3抗体、其抗体-药物偶联物及其医药用途 |
| CN114292334B (zh) * | 2021-12-24 | 2023-11-17 | 杭州贤至生物科技有限公司 | 抗可替宁特异性抗体、质粒载体及方法 |
| CN116813784B (zh) * | 2023-05-17 | 2024-03-01 | 星奕昂(上海)生物科技有限公司 | 靶向dll3的抗体及其应用 |
| CN116789836B (zh) * | 2023-08-14 | 2024-01-05 | 浙江时迈药业有限公司 | 针对dll3的抗体及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2844519A1 (fr) * | 2002-09-17 | 2004-03-19 | Bio Merieux | Proteine recombinante chimerique et diagnostic in vitro |
| US20120042416A1 (en) * | 2009-08-24 | 2012-02-16 | Fraunhofer-Gesellschaft zur Forderung der angewandten e.V. | Antibody fusion-mediated plant resistance against Oomycota |
| CA2775573A1 (en) * | 2009-10-09 | 2011-04-14 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-her 3 antibodies |
| EP3907242A1 (de) * | 2010-01-29 | 2021-11-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-dll3-antikörper |
| CN103003697A (zh) * | 2010-05-17 | 2013-03-27 | 得克萨斯系统大学董事会 | 来自动物的单克隆抗体的快速分离 |
| EP2817338B1 (de) * | 2012-02-24 | 2017-07-26 | AbbVie Stemcentrx LLC | Dll3-modulatoren und verwendungsverfahren |
| KR20160037130A (ko) * | 2013-02-22 | 2016-04-05 | 스템센트알엑스 인코포레이티드 | 신규한 항체 접합체 및 이의 용도 |
| CA2922544A1 (en) * | 2013-08-28 | 2015-03-05 | Stemcentrx, Inc. | Engineered anti-dll3 conjugates and methods of use |
| US9879087B2 (en) * | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| MA41613A (fr) * | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| CN106699888B (zh) * | 2015-07-28 | 2020-11-06 | 上海昀怡健康科技发展有限公司 | 一种pd-1抗体及其制备方法和应用 |
| TWI793062B (zh) * | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| US20190048094A1 (en) * | 2016-02-24 | 2019-02-14 | Oncomed Pharmaceuticals, Inc. | Redirecting immune responses |
| JOP20190009A1 (ar) * | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
-
2019
- 2019-04-30 US US15/733,747 patent/US20210047399A1/en active Pending
- 2019-04-30 WO PCT/US2019/029888 patent/WO2019217145A1/en unknown
- 2019-04-30 JP JP2020562110A patent/JP7455388B2/ja active Active
- 2019-04-30 EP EP19800438.4A patent/EP3790586A4/de active Pending
- 2019-04-30 SG SG11202009772PA patent/SG11202009772PA/en unknown
- 2019-04-30 BR BR112020021280-6A patent/BR112020021280A2/pt unknown
- 2019-04-30 CN CN201980031386.3A patent/CN112584860B/zh active Active
- 2019-04-30 MX MX2020011914A patent/MX2020011914A/es unknown
- 2019-04-30 CA CA3097193A patent/CA3097193A1/en active Pending
- 2019-04-30 AU AU2019267349A patent/AU2019267349A1/en active Pending
- 2019-04-30 KR KR1020207034344A patent/KR20210008367A/ko active Search and Examination
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022174167A (ja) | Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン | |
| US20210230269A1 (en) | Immune-stimulating monoclonal antibodies against human interleukin-2 | |
| JP5631733B2 (ja) | 抗ＥｐＣＡＭ抗体およびその使用 | |
| CN111944050B (zh) | 一种抗b7-h3抗体及其应用 | |
| RU2018124602A (ru) | Новые анти-pd-l1 антитела | |
| RU2013125306A (ru) | Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование | |
| JPWO2019173420A5 (de) | ||
| RU2015142815A (ru) | Лечение рака с использованием антител, связывающихся с поверхностным grp78 | |
| CA2595610A1 (en) | Antibodies directed to angiopoietin-2 and uses thereof | |
| JP2006507013A5 (de) | ||
| JP2010523096A5 (de) | ||
| WO2020114479A1 (zh) | 多特异性蛋白分子 | |
| JPWO2019173291A5 (de) | ||
| CN112094348B (zh) | 抗人Tim3抗体或其功能性片段及其应用 | |
| JP2017521054A5 (de) | ||
| IL310938A (en) | Anti-CCR8 antibodies and their uses | |
| JP2019512210A5 (de) | ||
| WO2021254481A1 (zh) | 抗Claudin18.2抗体以及其用途 | |
| CN103880956A (zh) | 抗muc1单克隆抗体及其轻链和重链可变区 | |
| JPWO2019217145A5 (de) | ||
| JP2021512652A5 (de) | ||
| BR112020001657A2 (pt) | Anticorpo contra cd147 humana, fragmento de ligação a antígeno do anticorpo, composição farmacêutica, uso do anticorpo ou do fragmento de ligação a antígeno,polinucleotídeo, vetor de expressão, célula hospedeira, método para produzir o anticorpo ou o fragmento de ligação a antígeno do mesmo, para prognosticar aresponsividade ao tratamento contra o câncer e para selecionar sujeitos para o tratamento contra o câncer, kit para determinar a responsividade ao tratamento contra o câncer, complexo de anticorpo-fármaco, e, anticorpo biespecífico | |
| CN113227148A (zh) | 抗gpc3抗体、其抗原结合片段及其医药用途 | |
| Takagi‐Maeda et al. | Novel cancer‐specific epidermal growth factor receptor antibody obtained from the serum of esophageal cancer patients with long‐term survival | |
| JPWO2020210067A5 (de) |